IQConsortium
The vision of the International Consortium for Innovation and Quality in Pharmaceutical Development is to be the leading science-based organization advancing innovative solutions to biomedical problems and enabling pharmaceutical companies to bring quality medicines to patients.
As a technically-focused organization of pharmaceutical and biotechnology companies, IQ advances science and technology to augment the capability of member companies to bring transformational solutions that benefit patients, regulators and the broader R&D community.
Statistician meeting prep-sheet: Introduction
Metabolism and Excretion of Therapeutic Peptides Current Industry Practices, Perspectives, and Recom
Leveraging Patient Centric Sampling: Clinical Drug Development & Decentralized Clinical Trials
Contemporary Opportunities & Challenges: Characterizing Crystallinity in Amorphous Solid Dispersions
Bioanalytical Considerations and Challenges for Cell Therapies & Immunogenicity Risk Assessment
A Metric for a Greener Future in Drug Manufacturing - iGAL 2.0
Perspective on Clinical Pharmacology & Pharmacometric Aspects of CAR-T & TCR-T Cellular Therapies
Therapeutic Protein Drug Interactions (TP-DIs)
Development of Ritonavir Pediatric Formulations
Advances in Coprocessed APIs & Proposals for Enabling Commercialization of Transformatative Tech
Considerations for Bioavailability & Bioequivalence Studies Age-Appropriate Pediatric Formulations
Predictive Dissolution Modeling: When and How?
Pediatric Excipient Selection Using Benefit/Risk Approach
Pediatric Dosage Forms "Out in the Wild" - What Really Happens in Clinical Practice
Preclinical Approaches to Suicidal Ideation & Behavior
Quantitative Evaluations of Immunogenicity Assessment
Regulatory Considerations for Pediatric Drugs and Combination Products
Best Pharmaceutical for Children Act (BPCA): A Pediatric Drug Development Program...the NIH Way
Extemporaneous Formulations in Pediatric Drug Development
Making Bitter Medicines Better for Everyone
Dissolution Method Troubleshooting: An Industry Perspective
Medication Use in Neonates: Small People, BIG Problems
Current Practices for QSP Model Assessment: An IQ Consortium Survey and Roundtable Discussion
QSP as an Integral Component of Clinical Development: Case Studies
PBPK in Drug Discovery and Development: A Pharmaceutical Industry Perspective
Scientific and Regulatory Considerations for Long Acting Injectable Suspensions 21Jul2023
Challenges and opportunities in mRNA delivery in the Gastrointestinal tract
Forging New Partnerships to Advance Pediatric Formulations Development
Pediatric Formulations Not Just Liquids Anymore
Nanomedicine Development Physicochemical Characterization Considerations